Please login to the form below
filgotinib
This page shows the latest filgotinib news and features for those working in and with pharma, biotech and healthcare.
EMA issues new guidance to limit use of JAK inhibitors for chronic inflammatory disorders
This includes Cibinqo (abrocitinib), Jyseleca (filgotinib), Olumiant (baricitinib), Rinvoq (upadacitinib) and Xeljanz (tofacitinib).
Latest news
-
NHS Scotland to offer Jyseleca for patients with moderate rheumatoid arthritis
NHS Scotland will now be able to offer Galapagos Biotech’s Jyseleca (filgotinib) to patients with moderate rheumatoid arthritis (RA), following a recommendation from the Scottish Medicines Consortium (SMC). ... We are delighted that people living with
-
Gilead’s Jyseleca is given a NICE recommendation for rheumatoid arthritis
Jyseleca (filgotinib) is an oral JAK inhibitor that can be administered as a monotherapy or used alongside another another common RA medicine called methotrexate. ... The FDA has expressed concerns regarding the overall benefit/risk profile of the
-
Galapagos mid-stage trial failure raises concerns for Gilead deal
Following the disappointing results, Galapagos has lost out on the funds, with more pressure piled onto the other focal drug of the Gilead alliance – filgotinib. ... However, earlier this year the US Food and Drug Administration rejected Gilead’s
-
Lilly halts most clinical trials as coronavirus disruption continues
Biotech company Galapagos also announced last week that is has also postponed multiple studies of its experimental, Gilead-partnered drug filgotinib, which is currently in a range of late-stage studies
-
MorphoSys drops Novartis-partnered drug in eczema after phase 2 miss
AbbVie’s Rinvoq (upadacitinib), Gilead/Galapagos’ filgotinib and Pfizer’s abrocitinib.
More from news
Approximately 3 fully matching, plus 28 partially matching documents found.
Latest Intelligence
-
Setting up for success in a post-Brexit, post-pandemic Britain
Recently, Galapagos and Gilead Sciences received a positive NICE recommendation for Jyseleca (filgotinib) for use on the NHS which, for the first time, will support access to an advanced therapy for
-
Cortellis Drugs to Watch in 2020 report
Sales are projected at $1.589bn in 2024. 5. Filgotinib from Gilead/Galapagos is an oral JAK1 inhibitor in regulatory review in the US, EU and Japan for rheumatoid arthritis Overactivation ... If approved, filgotinib will be a late entrant into a very
-
20 for 2020 – Five pharma leaders to watch in 2020
filgotinib for rheumatoid arthritis. ... and filgotinib’s anticipated launch this year meets expectations in the increasingly competitive market for JAK inhibitors.
-
European biotech: a new generation of leaders emerges
is its experimental JAK1 inhibitor filgotinib for rheumatoid arthritis. ... This will include broader commercial rights in Europe for filgotinib, due to be filed later this year, setting up a 2020 launch.
-
Drug launches to watch in 2019
Lilly’s already-approved Olumiant (baricitinib) and Pfizer’s PF-04965842 are rivals for Abbvie’s upadacitinib, but Gilead and Galapagos’ filgotinib (an AbbVie cast-off) now looks like the biggest ... Likewise, upadacitinib will face competition
More from intelligence
Approximately 0 fully matching, plus 6 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Exciting Medical Writer Career Opportunity for Postdoc, Medcomms
-
Highly competitive salary
- Market Access Director, six figure base salary and £5K joining b...
-
Highly competitive salary
- Lead Market Access Writer, £5K joining bonus, UK
-
Highly competitive salary
- Principal Medical Writer/ Scientific Lead, Medcomms, £5K joining...
-
Highly competitive salary
- World Health Organization releases latest set of COVID-19 guidelines
- BeiGene’s Brukinsa receives FDA approval for chronic lymphocytic leukaemia
- AstraZeneca/Daiichi Sankyo’s Enhertu approved by EC for advanced breast cancer
- Eli Lilly announces $450m investment in US manufacturing site
- Europe’s cancer community publishes new report on transforming patient care
- EU outlines measures to mitigate antibiotic shortage across Europe
- Innovative Trials comments on extra funding to increase access to clinical trials for cancer patients
- Gilead’s CAR-T cell therapy recommended by NICE for lymphoma
- JCVI recommends autumn COVID-19 vaccine booster for those at highest risk
- MIT researchers develop AI model to detect future lung cancer risk
- Merging global and local pharmacovigilance operations into a successful integrated approach
- Diversifying Healthcare AI with Federated Learning
- FDA and CDC investigate potential safety concern for Pfizer/BioNTech’s COVID-19 vaccine
- World Health Organization releases latest set of COVID-19 guidelines
- AbbVie and Eli Lilly leave UK’s voluntary drug pricing agreement
- EU to revise pharmaceuticals law amid antibiotic shortages
- European MPs call for urgent action against antimicrobial resistance
- The role of medical communications in building credibility for healthtech
PMHub
Hamell
Hamell is a full-service agency with a clear focus on delivering evidence-based, sustained behaviour change. So, whether you are looking...
Latest intelligence
- Virtual Steering Committee & Peer Influence Program
- In this customer story, we describe the methodology and results of our client’s ongoing Virtual Steering Committee & Peer Influence program....
- Meeting healthcare’s rising challenges
- The journey to discover novel therapies through digital innovation and ensure scientific advances achieve their potential...
- Report gives insights to address gaps in HCP engagement
- How does Pharma-HCP engagement need to evolve in today's digital landscape?...
